Upregulation of indoleamine 2,3-dioxygenase in hepatocyte during acute hepatitis caused by hepatitis B virus-specific cytotoxic T lymphocytes in vivo

Liver International

Volumn 29, Issue 2, 2009, Pages 277-283

  Iwamoto, Naoki ^a   Ito, Hiroyasu ^a   Ando, Kazuki ^a   Ishikawa, Tetsuya ^b   Hara, Akira ^a   Taguchi, Ayako ^a   Saito, Kuniaki ^c   Takemura, Masao ^a   Imawari, Michio ^d   Moriwaki, Hisataka ^a   Seishima, Mitsuru ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nagoya Kyoritsu Hospital   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocyte; Hepatitis B virus; Indoleamine 2,3 dioxygenase

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; RECOMBINANT GAMMA INTERFERON;

ACUTE HEPATITIS; ADOPTIVE TRANSFER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; HEPATITIS B VIRUS; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER PARENCHYMA; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALANINE TRANSAMINASE; ANIMALS; HEPATITIS B VIRUS; HEPATITIS, VIRAL, ANIMAL; HEPATOCYTES; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; KYNURENINE; MICE; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; UP-REGULATION;

EID: 58149489295     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01748.x     Document Type: Article

References (30)

1. Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340-4.
2. Lettau LA, McCarthy JG, Smith MH, et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med 1987; 317: 1256-62.
3. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995; 17: 261-81.
4. Ando K, Moriyama T, Guidotti LG, et al. Mechanisms of class I restricted immunopathology, a transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541-54.
5. Fujigaki S, Saito K, Sekikawa K, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001; 31: 2313-8.
6. Murray HW, Szuro-Sudol A, Wellner D, et al. Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun 1989; 57: 845-9.
7. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999; 20: 469-73.
8. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189: 1363-72.
9. Mellor AL, Sivakumar J, Chandler P, et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001; 2: 64-8.
10. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-101.
11. Grohmann U, Fallarino F, Bianchi R, et al. A defect in tryptophan catabolism impairs tolerance in nonobese diabetic mice. J Exp Med 2003; 198: 153-60.
12. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002; 86: 1691-6.
13. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873-6.
14. Yoshida R, Urade Y, Tokuda M, Hayaishi O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci USA 1979; 76: 4084-6.
15. Larrea E, Riezu-Boj JI, Gil-Guerrero L, et al. Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol 2007; 81: 3662-6.
16. Hissong BD, Byrne GI, Padilla ML, Carlin JM. Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1. Cell Immunol 1995; 160: 264-9.
17. Fujigaki S, Saito K, Takemura M, et al. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: Cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect Immun 2002; 70: 779-86.
18. Ito H, Ando K, Nakayama T, et al. Role of V alpha 14 NKT cells in the development of impaired liver regeneration in vivo. Hepatology 2003; 38: 1116-24.
19. Gregory SH, Wing EJ. IFN-gamma inhibits the replication of Listeria monocytogenes in hepatocytes. J Immunol 1993; 151: 1401-9.
20. Gregory SH, Barczynski LK, Wing EJ. Effector function of hepatocytes and Kupffer cells in the resolution of systemic bacterial infections. J Leukoc Biol 1992; 51: 421-4.
21. Heyes MP, Chen CY, Major EO, Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997; 326(Pt 2): 351-6.
22. Schutz G, Beato M, Feigelson P. Messenger RNA for hepatic tryptophan oxygenase: Its partial purification, its translation in a heterologous cell-free system, and its control by glucocorticoid hormones. Proc Natl Acad Sci USA 1973; 70: 1218-21.
23. Takikawa O, Yoshida R, Kido R, Hayaishi O. Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 1986; 261: 3648-53.
24. Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka M. Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects. Neurosurg Rev 1984; 7: 37-54.
25. Kakimi K, Lane TE, Wieland S, et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194: 1755-66.
26. Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 1992; 16: 655-63.
27. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196: 459-68.
28. Lee GK, Park HJ, Macleod M, Chandler P, Munn DH, Mellor AL. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology 2002; 107: 452-60.
29. Munn DH, Zhou M, Attwood JT, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281: 1191-3.
30. Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8 (+) T cell effector functions after antigen recognition in the liver. Immunity 2005; 23: 53-63.